KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung

Oncology Reports

Volumn 28, Issue 4, 2012, Pages 1187-1192

  Yokota, Keisuke ^a   Sasaki, Hidefumi ^a   Okuda, Katsuhiro ^a   Shimizu, Shigeki ^b   Shitara, Masayuki ^a   Hikosaka, Yu ^a   Moriyama, Satoru ^a   Yano, Motoki ^a   Fujii, Yoshitaka ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

Author keywords

Adenocarcinoma; Chromosomal rearrangement; KIF5B RET; Non small cell lung cancer

Indexed keywords

B RAF KINASE; ENDOTHELIAL CELL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN;

ADULT; AGED; ARTICLE; BRAF GENE; BREAST CANCER; CANCER SURVIVAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EGFR GENE; EML4 ALK FUSION GENE; EXON; FEMALE; FUSION GENE; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC IDENTIFICATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; KIF5B GENE; KIF5B RET FUSION GENE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; ONCOGENE K RAS; ONCOGENE NEU; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RET GENE;

ADENOCARCINOMA; ADENOCARCINOMA, PAPILLARY; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COLORECTAL NEOPLASMS; EXONS; FEMALE; GENE FUSION; HUMANS; KINESIN; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING; THYROID NEOPLASMS; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 84866450872     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1908     Document Type: Article

References (34)

1. Lee YJ, Kim JH, Kim SK, et al: Lung cancer in never smokers: change of a mindset in the molecular era. Lung Cancer 72: 9-15, 2011.
2. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004. (Pubitemid 38720929)
3. Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561-566, 2007. (Pubitemid 47206930)
4. Wong DW, Leung EL, So KK, et al: The EML4-ALK fusion gene is involved in various histologic types of lung cancers from non smokers with wild-type EGFR and KRAS. Cancer 115: 1723-1733, 2009.
5. Pao W and Girard N: New driver mutations in non-small-cell lung cancer. Lancet Oncol 12: 175-180, 2011.
6. Shaw AT, Yeap BY, Solomon BJ, et al: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12: 1004-1012, 2011.
7. Ju YS, Lee WC, Shin JY, et al: Fusion of KIF5B and RET transforming gene in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 22: 436-445, 2012.
8. Lipson D, Capelletti M, Yelensky R, et al: Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18: 382-384, 2012.
9. Kohno T, Ichikawa H, Totoki Y, et al: KIF5B-RET fusions in lung adenocarcinoma. Nat Med 18: 375-377, 2012.
10. Takeuchi K, Soda M, Togashi Y, et al: RET, ROS1 and ALK fusions in lung cancer. Nat Med 18: 378-381, 2012.
11. Sasaki H, Endo H, Konishi A, et al: EGFR mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin Cancer Res 11: 2924-2929, 2005. (Pubitemid 40525194)
12. Sasaki H, Shimizu S, Endo K, et al: EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer 118: 180-184, 2006. (Pubitemid 41681596)
13. Sasaki H, Hikosaka Y, Kawano O, Moriyama S, Yano M and Fujii Y: Evaluation of Kras mutation and copy number gain in non-small cell lung cancer. J Thorac Oncol 6: 15-20, 2011.
14. Sasaki H, Okuda K, Kawano O, et al: Nras and Kras mutation in Japanese lung cancer patients: genotyping analysis using LightCycler. Oncol Rep 18: 623-628, 2007.
15. Sasaki H, Kawano O, Endo K, et al: Uncommon V599E Braf mutations in Japanese patients with lung cancer. J Surg Res 133: 203-206, 2006.
16. Grieco M, Santoro M, Berlingieri MT, et al: PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60: 557-563, 1990.
17. Alberti L, Carniti C, Miranda C, Roccato E and Pierotti MA: RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol 195: 168-186, 2003. (Pubitemid 36384291)
18. Zeng Q, Cheng Y, Zhu Q, et al: The relationship between overexpression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer. J Int Med Res 36: 656-664, 2008.
19. Dawson DM, Lawrence EG, MacLennan GT, et al: Altered expression of RET proto-oncogene product in prostatic intraepithelial neoplasia and prostate cancer. J Natl Cancer Inst 90: 519-523, 1998. (Pubitemid 28182545)
20. Ohshima Y, Yajima I, Takeda K, Kumasaka M, Matsumoto M and Kato M: c-RET molecule in malignant melanoma from oncogenic RET-carrying transgenic mice and human cell lines. PLoS One 5: e10279, 2010.
21. Tanizaki J, Okamoto I, Sakai K and Nakagawa K: Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. Br J Cancer 105: 807-813, 2011.
22. Henderson YC, Ahn SH, Kang Y and Clayman GL: Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. Clin Cancer Res 14: 4908-4914, 2008.
23. Carlomagno F, Anaganti S, Guida T, et al: BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98: 326-334, 2006. (Pubitemid 43338212)
24. Kim DW, Jo YS, Jung HS, et al: An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91: 4070-4076, 2006. (Pubitemid 44536887)
25. Dawson S, Conus NM, Toner GC, Raleigh JM, Hicks RJ, McArthur G and Rischin D: Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anticancer Drugs 19: 547-552, 2008. (Pubitemid 351556406)
26. Takeuchi K, Choi YL, Togashi Y, et al: KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15: 3143-3149, 2009.
27. Score J, Curtis C, Waghorn K, et al: Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 20: 827-832, 2006.
28. Takahashi T, Sonobe M, Kobayashi M, et al: Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 17: 889-897, 2010.
29. Inamura K, Takeuchi K, Togashi Y, et al: EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 3: 13-17, 2008.
30. Inamura K, Takeuchi K, Togashi Y, et al: EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 22: 508-515, 2009.
31. Yoshida A, Tsuta K, Nakamura H, et al: Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 35: 1226-1234, 2011.
32. Camidge DR, Kono SA, Lu X, et al: Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 6: 774-780, 2011.
33. + lung adenocarcinoma. J Thorac Oncol 7: 90-97, 2012.
34. Wu SG, Kuo YW, Chang YL, et al: EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. J Thorac Oncol 7: 98-104, 2012.